The goal of the research activities at the Laboratory of Molecular and Cellular Therapy (LMCT) is to develop innovative immunotherapy strategies.
The strategies under development include:
1) ex vivo and in vivo engineering of dendritic cells for immune activation and
2) engineering of the tumor micro-environment to facilitate anti-tumor immune responses.
Technologies such as mRNA, lentiviral vectors and single domain antibodies (better known as nanobodies) are employed for these purposes.
For more information: click here